In addition to these approved uses, clinical trials in people with specific health conditions have shown that GLP-1s offer additional benefits, such as: Reducing the risk of heart attack and stroke Slowing kidney disease progression Treating moderate-to-advanced liver fibrosis Treating moderate-to-severe obstructive sleep apnea Also, semaglutide (Wegovy) is FDA-approved for chronic weight management in adolescents age 12 and older with obesity
and incorporation of non-natural amino acids like biphenylalanine (Bip) (36 entries), pyroglutamic acid (pGlu) (27 entries), sarcosine (Sar) (45 entries), ornithine (Orn) (12 entries), norleucine (Nle) (4 entries), etc
Therefore, antioxidants may be valuable therapeutics for OA
Article referenced in the comments below
The first phase of the reactors were 30* 2000L~5000L, The contract output value is 50 million annually, factory has passed the audit from public listed company domestic and abroad
Mutation Research